BactiQuant (BACTIQ) Q2 2026 TU earnings summary

Executive summary

• Revenue for H1 2026 reached DKK 5.3 million, representing 29% growth year-over-year, driven primarily by recurring revenue in the Pharma segment.

• Strong growth in consumables for BactiQuant Online, with sales more than tripling compared to H1 2025.

Financial highlights

• Total revenue for H1 2026: DKK 5.3 million, up from DKK 4.1 million in H1 2025.

• Recurring revenue grew 46% year-over-year, reaching DKK 3.2 million.

• Hardware sales declined 6% year-over-year due to timing differences.

• Liquidity as of June 30, 2026: DKK 11.9 million.

Outlook and guidance

• 2026 revenue guidance maintained at DKK 10–13 million.

• Expected EBITDA for 2026 in the range of DKK -7 to -10 million.

• Sufficient liquidity projected until mid-2027, with ongoing assessment of future capital needs.